Table 1: Evaluation of clinical failures
No pathology | Presence of pain | Swelling | Sinus tract opening | Presence of mobility | Total | ||||||||
Formocresol | 17 | – | 1 | – | – | 18 | |||||||
Pulpotec | 17 | – | 1 | – | – | 18 | |||||||
Mineral trioxide aggregate | 18 | – | – | – | – | 18 | |||||||
Emdogain | 15 | – | 1 | 2 | – | 18 |